These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 26413789

  • 1. Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.
    Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ.
    J Med Econ; 2016; 19(2):121-34. PubMed ID: 26413789
    [Abstract] [Full Text] [Related]

  • 2. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B, Kragh N, McConnachie CC, Valentine WJ, Rossi MC, Montagnoli R.
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [Abstract] [Full Text] [Related]

  • 3. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Jul; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.
    Tzanetakos C, Melidonis A, Verras C, Kourlaba G, Maniadakis N.
    BMC Health Serv Res; 2014 Sep 22; 14():419. PubMed ID: 25245666
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
    Steen Carlsson K, Persson U.
    J Med Econ; 2014 Sep 22; 17(9):658-69. PubMed ID: 24950434
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov 22; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 10. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL, Willis WD, Foos V.
    Curr Med Res Opin; 2010 Jan 22; 26(1):163-75. PubMed ID: 19919377
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug 22; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
    Zueger PM, Schultz NM, Lee TA.
    Pharmacoeconomics; 2014 Nov 22; 32(11):1079-91. PubMed ID: 25052903
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.
    Mezquita Raya P, Pérez A, Ramírez de Arellano A, Briones T, Hunt B, Valentine WJ.
    Diabetes Ther; 2013 Dec 22; 4(2):417-30. PubMed ID: 24132613
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.
    Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N.
    Diabetes Obes Metab; 2017 Jun 22; 19(6):842-849. PubMed ID: 28124820
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Bargiota A, Kourlaba G, Gourzoulidis G, Maniadakis N.
    Clin Drug Investig; 2018 Jan 22; 38(1):67-77. PubMed ID: 29080210
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH, Verheggen BG, Charokopou M, Gibson D, Grandy S, Kartman B.
    J Med Econ; 2016 Dec 22; 19(12):1127-1134. PubMed ID: 27310712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.